Future Directions and Pipeline Therapies for Hidradenitis Suppurativa.

Dermatologic clinics 2025 Vol.43(2) p. 359-371

Nguyen KT, Jaguan D, Goldfarb N

관련 도메인

Abstract

Hidradenitis suppurativa (HS) is a painful, autoinflammatory condition with dramaticimpact on quality of life. As of January 1, 2024, there are 25 phase I-III clinical trials for topical and systematic medications in the management of HS. Only three medications, adalimumab, secukinumab and bemikizumab, are currently approved by the United States Food and Drug Administration for the treatment of moderate to severe HS. In addition, 15 nonmedication-based studies are ongoing, including those for various surgical techniques, botulinum toxin, laser and light-based therapies, differing wound care methods, and a variety of complementary and alternative medicine practices for HS.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
해부 bemikizumab scispacy 1
합병증 Hidradenitis suppurativa scispacy 1
합병증 wound scispacy 1
약물 adalimumab scispacy 1
약물 secukinumab scispacy 1
약물 botulinum scispacy 1
질환 Hidradenitis C0085160
Hidradenitis
scispacy 1
질환 Hidradenitis suppurativa C0162836
Hidradenitis Suppurativa
scispacy 1
질환 nonmedication-based scispacy 1

MeSH Terms

Humans; Hidradenitis Suppurativa; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Adalimumab; Laser Therapy; Complementary Therapies; Quality of Life

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문